Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation

Mahlet Z Tamirat1, Marika Koivu2,3,4, Klaus Elenius2,3,5

  • 1Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.

Plos One
|September 20, 2019
PubMed

Insights

A common deletion mutation in epidermal growth factor receptor (EGFR) stabilizes its active conformation, enhancing kinase activity and ATP binding. This finding explains increased sensitivity to targeted therapies in non-small cell lung cancer.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Structural Biology

Background:

  • Epidermal growth factor receptor (EGFR) is crucial for cell growth and survival.
  • EGFR mutations, particularly deletions, are linked to non-small cell lung cancer (NSCLC) development.
  • Understanding mutation-induced structural changes is key to targeted cancer therapy.

Purpose of the Study:

  • To investigate the structural impact of the EGFR Δ746ELREA750 deletion mutation.
  • To elucidate how this mutation increases EGFR kinase activity.
  • To correlate structural findings with observed drug responses in NSCLC.

Main Methods:

  • Molecular dynamics simulations were employed to model wild-type and mutant EGFR.
  • Simulations analyzed the conformational stability and dynamics of the EGFR kinase domain.
  • Binding interactions with ATP and effects of tyrosine kinase inhibitors were assessed.

Main Results:

  • The Δ746ELREA750 deletion stabilizes the active 'αC-in' conformation of the EGFR kinase domain.
  • The mutation enhances the stability of a key salt bridge (E762-K745) critical for kinase activity.
  • Δ746ELREA750 EGFR exhibits stronger ATP binding and increased sensitivity to active-site inhibitors compared to wild-type.

Conclusions:

  • The Δ746ELREA750 deletion promotes a shift towards the active EGFR conformation, prolonging its active state.
  • Structural stabilization by the mutation underlies increased kinase activity and therapeutic vulnerability.
  • Findings support the mechanism of enhanced efficacy of EGFR inhibitors in NSCLC patients with this mutation.

Related Concept Videos